Formulation: A solid
Formal Name: 2-hydroxy-N-(4-hydroxyphenyl)-benzamide
Purity: ≥95%
Formula Markup: C13H11NO3
Formula Weight: 229,2
Shelf life (days): 1460
CAS Number: 526-18-1
Notes: Osalmid is an inhibitor of ribonucleoside-diphosphate reductase subunit M2 (RRM2; IC50 = 8.2 µM).{67394} It decreases hepatitis B virus (HBV) DNA replication in infected HepG2 2.2.15 cells (EC50 = 45.8 µM) and reduces HBV DNA levels in the supernatant and lysates of infected HepG2 2.2.15 cells (EC50s = 11.1 and 16.5 µM, respectively). Osalmid inhibits the replication of HBV resistant to the nucleoside reverse transcriptase inhibitor 3TC (lamivudine; Item No. 18514) in infected HepG2 cells (EC50 = 19.8 µM). It reduces the proliferation of HepG2, Huh7, and HCCLM3 cells in a concentration-dependent manner and decreases the proliferation of a variety of esophageal squamous cell carcinoma cells (IC50s = 144.8-182.3 µM).{67395,67396} Osalmid (400 mg/kg per day) reduces HBV DNA levels in serum and liver tissues in a transgenic mouse model of HBV infection. Intragastric administration of osalmid (200 mg/kg per day), in combination with radiation, reduces tumor growth in radiation-sensitive and -resistant KYSE-150 esophageal squamous cell carcinoma mouse xenograft models.{67396}